Vijetha Karen Kitchley, M.Sc.
Editorial Office, The ACTO Times
International PhD Program in Cell Therapy & Regenerative Medicine, Taipei Medical University, Taiwan

Introduction 

Mesenchymal stem cells (MSCs) have long been at the forefront of regenerative medicine due to their multipotency and immunomodulatory properties[1, 2]. However, direct stem cell transplantation is often limited by challenges such as donor-to-donor heterogeneity, diminished viability post-transplantation, potential immunogenicity, and the risk of teratoma formation[1, 2]. To circumvent these hurdles, induced pluripotent stem cells (iPSCs) and iPSC-derived mesenchymal stem cells (iMSCs) have emerged as powerful alternatives, providing a highly scalable and patient-specific cellular source. Concurrently, it has become evident that the regenerative benefits of stem cells are largely mediated by paracrine factors rather than direct cellular engraftment[2, 3]. Chief among these paracrine effectors are exosomes—nanoscale extracellular vesicles that inherit the therapeutic properties of their parental cells but offer a safer, cell-free therapeutic modality without the risk of tumorigenesis or severe immune rejection[1, 2].

Biogenesis, Composition, and Mechanisms of Action 

Exosomes, typically ranging from 30 to 180 nm in diameter, are formed through the endosomal pathway, wherein multivesicular bodies (MVBs) fuse with the plasma membrane to release vesicles into the extracellular space[2, 4]. The lipid bilayer of exosomes is enriched with cholesterol and sphingomyelin, which protects their internal cargo from enzymatic degradation. Exosomes carry a complex and highly specific payload consisting of lipids, proteins (such as tetraspanins CD9, CD63, and CD81, and heat shock proteins like HSP70), and nucleic acids, most notably microRNAs (miRNAs)[2, 4].

Upon release, exosomes communicate with target cells through endocytosis, direct membrane fusion, or receptor-ligand interactions[1, 2, 4]. By transferring their bioactive cargo, stem cell-derived exosomes (SC-Exos) can alter gene expression in recipient cells, activating critical intracellular signaling cascades—such as the PI3K/Akt, Wnt/β-catenin, and ERK1/2 pathways—which drive cell survival, proliferation, and tissue regeneration.

Cardiovascular Diseases and Ischemic Repair 

Cardiovascular diseases (CVDs) remain the leading cause of global mortality[3]. While engineered cardiac tissues and iPSC-derived cardiomyocytes offer potential for heart remuscularization, these cellular approaches are sometimes complicated by low engraftment rates and the induction of ventricular tachyarrhythmias. Consequently, exosome-based therapies are gaining traction as a safer alternative. Exosomes derived from iPSCs, iMSCs, and iPSC-derived cardiomyocytes have demonstrated profound cardioprotective effects following myocardial infarction (MI). By delivering specific cardioprotective miRNAs, such as miR-21 and miR-210, these exosomes reduce cardiomyocyte apoptosis, attenuate oxidative stress, and decrease fibrotic remodeling[4].

Beyond the heart, exosome therapy significantly enhances angiogenesis in peripheral ischemic conditions. For instance, in models of hindlimb ischemia, exosomes from iPSC-derived endothelial cells heavily enriched with miR-199b-5p were shown to promote microvessel density and blood perfusion by upregulating the vascular endothelial growth factor receptor 2 (VEGFR2) pathway[2, 4].

Orthopedics and Musculoskeletal Regeneration 

In the musculoskeletal system, iMSC-derived exosomes and SC-Exos facilitate robust bone and cartilage repair. For bone defect therapies, combining exosomes with tricalcium phosphate (β-TCP) scaffolds significantly accelerates osteogenesis by activating the PI3K/Akt signaling pathway in endogenous bone marrow MSCs[2, 4]. Furthermore, in conditions like glucocorticoid-induced osteonecrosis of the femoral head, iMSC-derived exosomes prevent bone loss and promote local vascularization[1, 2, 4].

Exosomes also present a promising disease-modifying strategy for osteoarthritis (OA). Interestingly, exosomes derived from iMSCs have been shown to outperform those from adult synovial membrane MSCs, exerting superior effects in stimulating chondrocyte proliferation and migration while inhibiting matrix-degrading enzymes and cellular apoptosis[1, 2].

Neurology and Neurodegeneration 

The therapeutic application of exosomes in the central nervous system spans both acute injuries and chronic neurodegenerative diseases. In ischemic stroke and traumatic brain injury (TBI), exosome administration reduces infarct volume, suppresses neuroinflammation, and promotes neurogenesis[1]. iPSC-derived neural stem cell exosomes (iNSC-Exos) have also shown remarkable ability in restoring motor function and improving structural outcomes post-stroke[4].

In Alzheimer’s disease (AD), exosome therapies have demonstrated the ability to clear amyloid-beta plaques and rescue synaptic dysfunction[1]. However, the role of exosomes in neurodegeneration is notably dual-faceted. While healthy SC-Exos are neuroprotective, exosomes secreted by diseased neurons can act as pathogenic mediators. For example, exosomes derived from iPSC neurons bearing mutant Tau proteins have been shown to propagate Tau pathology and induce neurodegeneration in healthy neural tissues[4].

Plastic Surgery and Cutaneous Wound Healing 

For cutaneous wounds, particularly recalcitrant diabetic ulcers, iMSC- and iPSC-derived exosomes accelerate healing by driving the transition from the inflammatory phase to the proliferative and remodeling phases[1, 4]. Exosome treatment upregulates the secretion of type I and III collagen and elastin, accelerating re-epithelialization and reducing overall scar formation[2, 4]. In vitro studies confirm that iMSC-exosomes enhance the migration and cell cycle progression of human dermal fibroblasts and keratinocytes (HaCaT cells) more effectively than adult MSC-exosomes, primarily via the ERK1/2 and Akt/HIF-1α pathways.

Immunomodulation: The Core of Exosome-Mediated Repair 

A unifying mechanism underlying the therapeutic success of SC-Exos across these diverse tissues is their profound impact on the innate immune system. Tissue regeneration is heavily dependent on the fine-tuning of local inflammation, specifically the polarization of macrophages[3]. Following acute injury, pro-inflammatory M1 macrophages clear necrotic debris but can exacerbate tissue damage if overactive. Exosomes facilitate the critical phenotypic switch from M1 to anti-inflammatory M2 macrophages, which secrete IL-10 and TGF-β to promote wound healing, neovascularization, and organized matrix deposition. Transcriptomic studies indicate that exosomal miRNAs, such as miR-181b, are key mediators of this macrophage polarization[3].

Challenges and Future Perspectives

Despite these highly promising developments, the clinical translation of iPSC- and iMSC-derived exosomes faces several challenges. Primary among these is the low yield of exosome production in conventional cell cultures, coupled with the lack of standardized protocols for isolation, characterization, and batch-to-batch consistency[1, 2]. To address production bottlenecks, researchers are exploring exosome manipulation techniques, such as the overexpression of the ALIX protein in iPSCs, which significantly enhances exosome yield and protective protein content[4]. Another innovative solution is the generation of cell-engineered nanovesicles (CENVs) created by the serial extrusion of iPSCs, which mimic exosomal properties but allow for massive scalability[4].

Finally, while exosomes themselves are largely non-immunogenic, generating universal, “off-the-shelf” iPSC lines for both cell and exosome therapies remains a priority. Recent advances in CRISPR/Cas9 gene editing to knock out Human Leukocyte Antigens (HLA-I and HLA-II) are paving the way for hypoimmunogenic universal cells that evade immune rejection[3].

Conclusion

 Induced pluripotent and mesenchymal stem cell-derived exosomes represent a paradigm shift in regenerative medicine. By harnessing the potent, multi-targeted paracrine effects of stem cells while avoiding the pitfalls of direct cell transplantation, iPSC- and iMSC-derived exosomes offer a highly versatile, cell-free platform to treat cardiovascular, musculoskeletal, neurological, and cutaneous diseases. Advancements in exosome engineering and scalable manufacturing will be crucial for realizing their full clinical potential.

References

1. Tan, F., et al., Clinical applications of stem cell-derived exosomes. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 17.
2. Aldoghachi, A.F., et al., Current developments and therapeutic potentials of exosomes from induced pluripotent stem cells-derived mesenchymal stem cells. J Chin Med Assoc, 2023. 86(4): p. 356-365.
3. Germena, G. and R. Hinkel, iPSCs and Exosomes: Partners in Crime Fighting Cardiovascular Diseases. Journal of Personalized Medicine, 2021. 11(6): p. 529.
4. Wang, A.Y.L., Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases. International Journal of Molecular Sciences, 2021. 22(4): p. 1769.